calostro

Reported Uses

• NOTE: see Herb & Supplement Effectiveness Rating Definitions table
• aging [Insufficient Evidence]
• athletic performance [Insufficient Evidence]
• autism spectrum disorder [Insufficient Evidence]
• BPH [Insufficient Evidence]
• child growth [Insufficient Evidence]
• cognitive function [Insufficient Evidence]
• critical illness (trauma) [Insufficient Evidence]
• dental plaque [Insufficient Evidence]
• diabetes mellitus, type 2 [Insufficient Evidence]
• diarrhea, HIV/AIDS-related [Possibly Effective]
• diarrhea, infectious [Possibly Effective]
• diarrhea, rotaviral [Possibly Effective]
• dry eye dz [Insufficient Evidence]
• exercise-induced respiratory infection [Possibly Effective]
• graft-versus-host dz [Insufficient Evidence]
• hematopoietic stem cell transplant [Insufficient Evidence]
• human papilloma virus [Insufficient Evidence]
• infection, chemo-related [Insufficient Evidence]
• influenza [Insufficient Evidence]
• lichen planus [Insufficient Evidence]
• malnutrition [Insufficient Evidence]
• multiple sclerosis [Insufficient Evidence]
• muscle strength [Insufficient Evidence]
• necrotizing enterocolitis prevention [Possibly Ineffective]
• oral mucositis [Insufficient Evidence]
• physical performance [Insufficient Evidence]
• prematurity [Insufficient Evidence]
• psychological well-being [Insufficient Evidence]
• sepsis [Possibly Ineffective]
• shigellosis [Insufficient Evidence]
• short bowel syndrome [Possibly Ineffective]
• Sjogren syndrome [Insufficient Evidence]
• traveler's diarrhea prophylaxis [Insufficient Evidence]
• ulcerative colitis [Insufficient Evidence]
• URI prevention [Insufficient Evidence]
• vaginal atrophy [Insufficient Evidence]
• wound healing [Insufficient Evidence]

Reported Doses

Safety/efficacy may not be established; reported doses may be derived from limited or potentially inadequate studies w/ variable regimens, multi-ingredient products, or where concentration of active ingredients may vary widely

Effectiveness Ratings

[see Herb & Supplement Effectiveness Rating Definitions table]

athletic performance

[Insufficient Evidence]

Dose: 10-60 g PO qd; Alt: 3.2 g PO qd

autism spectrum disorder

[Insufficient Evidence]

Dose: 5.1-10.8 g PO qd; Info: for pts 3-11 yo; used w/ Bifidobacterium infantis

child growth

[Insufficient Evidence]

Dose: 5.7 g PO bid; Info: for pts 9 mo; used w/ whole egg powder 4.3 g PO bid

critical illness (trauma)

[Insufficient Evidence]

Dose: 20 g PO qd

diabetes mellitus, type 2

[Insufficient Evidence]

Dose: 5 g PO bid; Info: give on empty stomach

diarrhea, HIV/AIDs-related

[Possibly Effective]

Dose: 10 g PO qid x21 days for HIV-related Cryptosporidium parvum diarrhea; Alt: 10-30 g PO qd x10-21 days for HIV-related cryptosporidial diarrhea

diarrhea, infectious

[Possibly Effective]

Dose: 3 g PO qd x1-4wk in pts 1-2 yo; 3 g PO bid x1-4wk in pts 3-6 yo; Alt: 7 g PO tid x14 days in pts 1 mo-18 yo for enterotoxigenic Escherichia coli diarrhea; 0.5 g/kg/day PO qd x1wk in pts 3-6 mo

diarrhea, rotaviral

[Possibly Effective]

Dose: 10 g PO qd in divided doses x4 days; Alt: 100 mL PO tid x3 days; 20 mL PO qd x2wk; Info: for peds pts up to 30 mo

exercise-induced respiratory infection

[Possibly Effective]

Dose: 10-20 g PO qd x8-12wk

human papilloma virus

[Insufficient Evidence]

Dose: apply topically 2x/wk x6mo

influenza

[Insufficient Evidence]

Dose: 400 mg PO qd x8wk

malnutrition

[Insufficient Evidence]

Dose: 40 mg/kg/dose PO qd x3mo; Info: for pts 1-10 yo

multiple sclerosis

[Insufficient Evidence]

Dose: 100 mL PO qd

oral mucositis

[Insufficient Evidence]

Dose: 0.5-1 g/kg/day PO qd x4wk

physical performance

[Insufficient Evidence]

Dose: 60 g PO qd

ulcerative colitis

[Insufficient Evidence]

Dose: 100 mL enema PR bid x4wk; Info: 10% enema

URI prevention

[Insufficient Evidence]

Dose: 3 g PO qd x4wk in pts 1-2 yo; 3 g PO bid x4wk in pts 3-6 yo; 30 g PO bid x8wk in pts 18 yo and older

vaginal atrophy

[Insufficient Evidence]

Dose: apply 2 mL (1% cream) PV qd; Alt: apply 2.3% gel PV qd